Motavizumab Reduces RSV Infection Severity in Mice
Author Information
Author(s): Asunción Mejías, Susana Chávez-Bueno, Martin B. Raynor, John Connolly, Peter A. Kiener, Hasan S. Jafri, Octavio Ramilo
Primary Institution: University of Texas Southwestern Medical Center at Dallas
Hypothesis
The administration of motavizumab will modify the immune response and reduce disease severity in RSV-infected mice.
Conclusion
Prophylactic administration of motavizumab significantly decreased RSV replication and cytokine responses, preventing clinical disease in mice.
Supporting Evidence
- Motavizumab significantly reduced RSV replication in treated mice.
- Lower concentrations of several cytokines were observed in the motavizumab group compared to untreated controls.
- Clinical disease was completely prevented in mice treated with motavizumab.
Takeaway
This study shows that a special medicine called motavizumab can help mice fight off a virus that makes them sick by lowering the amount of bad stuff in their bodies.
Methodology
BALB/c mice were inoculated with RSV and treated with motavizumab; cytokine levels were measured in bronchoalveolar lavage and serum samples.
Limitations
The study was conducted in a mouse model, which may not fully represent human responses to RSV.
Participant Demographics
Seven-week-old female BALB/c mice.
Statistical Information
P-Value
p<0.05
Confidence Interval
[2.22–2.53]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website